Evidence map›Paper›PMID 26349906›Full record

ArticleScientific reports2015

Development and Characterization of a Novel in vitro Progression Model for UVB-Induced Skin Carcinogenesis.

Nikhil Tyagi, Arun Bhardwaj, Sanjeev K Srivastava, Sumit Arora, Saravanakumar Marimuthu, Sachin K Deshmukh, Ajay P Singh, James E Carter, Seema Singh

Abstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Exploring the Functions of Mutant p53 throughCurrent issues in molecular biology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Effects ofJournal of microbiology and biotechnology · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Role ofNon-coding RNA research · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nikhil TyagiDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.
Arun BhardwajDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.
Sanjeev K SrivastavaDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.
Sumit AroraDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.
Saravanakumar MarimuthuDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.
Sachin K DeshmukhDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.
Ajay P SinghDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.
James E CarterDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama 36688, USA.
Seema SinghDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.

Funding

Targeting tumor-stromal interaction for pancreatic cancer therapyR01CA175772 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2014 to 2018
$1.9M
Molecular determinant of racial disparity in prostate cancerU01CA185490 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2014 to 2018
$1.7M
Myb, a key driver of pancreatic cancer progression and metastasisR21CA167137 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2012 to 2013
$346k
Chemoprotective role of silver nanoparticles in UV radiation-induced skin carcinoR03CA186233 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, SEEMA · 2014 to 2015
$151k
NCI NIH HHS CA167137NCI NIH HHS CA175772NCI NIH HHS CA185490NCI NIH HHS CA186233NCI NIH HHS R01 CA175772NCI NIH HHS R03 CA186233NCI NIH HHS R21 CA167137NCI NIH HHS U01 CA185490
6 · The paper itself

Abstract

Epidemiological studies suggest ultraviolet B (UVB) component (290-320 nm) of sun light is the most prevalent etiologic factor for skin carcinogenesis--a disease accounting for more than two million new cases each year in the USA alone. Development of UVB-induced skin carcinoma is a multistep and complex process. The molecular events that occur during UVB-induced skin carcinogenesis are poorly understood largely due to the lack of an appropriate cellular model system. Therefore, to make a progress in this area, we have developed an in vitro model for UVB-induced skin cancer using immortalized human epidermal keratinocyte (HaCaT) cells through repetitive exposure to UVB radiation. We demonstrate that UVB-transformed HaCaT cells gain enhanced proliferation rate, apoptosis-resistance, and colony- and sphere-forming abilities in a progressive manner. Moreover, these cells exhibit increased aggressiveness with enhanced migration and invasive potential and mesenchymal phenotypes. Furthermore, these derived cells are able to form aggressive squamous cell carcinoma upon inoculation into the nude mice, while parental HaCaT cells remain non-tumorigenic. Together, these novel, UVB-transformed progression model cell lines can be very helpful in gaining valuable mechanistic insight into UVB-induced skin carcinogenesis, identification of novel molecular targets of diagnostic and therapeutic significance, and in vitro screening for novel preventive and therapeutic agents.

Indexed as

AnimalsApoptosisCell Line, TumorCell MovementCell ProliferationCell Transformation, NeoplasticDisease Models, AnimalDisease ProgressionEpithelial-Mesenchymal TransitionHeterograftsHumansIn Vitro TechniquesMiceSkin NeoplasmsUltraviolet Rays

Identifiers

PMID26349906
PMCPMC4563561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.